Five-year visual outcome of treatment for retinopathy of prematurity in infants weighing less than 500 g at birth: A multicenter cohort study from J-CREST-Reference-Cited by-同舟云学术

Five-year visual outcome of treatment for retinopathy of prematurity in infants weighing less than 500 g at birth: A multicenter cohort study from J-CREST

Published:2023-12-06 Issue: Volume: Page:
ISSN:0275-004X
Container-title:Retina
language:en
Short-container-title:

Author:

Tomioka Mizuki¹²,Murakami Tomoya¹²^ORCID,Okamoto Fumiki¹³,Kinoshita Takamasa¹⁴,Shinomiya Kayo¹⁵,Nishi Tomo¹⁶,Jujo Tatsuya¹⁷,Obata Shumpei¹⁸,Tsukitome Hideyuki¹⁹,Ogura Shuntaro¹¹⁰,Ueda Kaori¹¹¹,Ishii Ryota¹²,Oshika Tetsuro¹²

Affiliation:

1. Japan Clinical Retina Study (J-CREST) group

2. Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan

3. Department of Ophthalmology, Nippon Medical School, Tokyo, Japan

4. Department of Ophthalmology, Sapporo City General Hospital, Sapporo, Japan

5. Department of Ophthalmology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan

6. Department of Ophthalmology, Nara Medical University, Nara, Japan

7. Department of Ophthalmology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan

8. Department of Ophthalmology, Shiga University of Medical Science, Otsu, Japan

9. Department of Ophthalmology, Graduate School of Medicine, Mie University, Tsu, Japan

10. Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

11. Division of Ophthalmology, Department of Surgery, Graduate School of Medicine, Kobe University, Kobe, Japan

12. Department of Biostatistics, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan

Abstract

Purpose: To investigate the 5-year treatment outcomes of retinopathy of prematurity (ROP) in infants <500 g birth weight and compare laser and anti-vascular endothelial growth factor (VEGF) therapies. Methods: A multicenter retrospective study comprised 24 eyes of 13 patients treated for type 1 ROP, followed for 5 years. Initial treatment was laser and anti-VEGF in 13 and 11 eyes, respectively. Data collected included sex, birth characteristics, ROP characteristics at the time of treatment, best-corrected visual acuity (BCVA), spherical equivalent (SE), and astigmatism at 5 years post-treatment. Results: Median BCVA was 0.15 logMAR (IQR, 0.0–0.5). Snellen BCVA was ≥20/40 in 73% and ≥20/20 in 27% of eyes. Median SE was -2.37 (IQR, -6.1–-0.1); 75% had myopia (≤ -0.5 D), and 25% had high myopia (≤ -6.0 D). Median astigmatism was 1.25 (IQR, 0.9–3.0); 46% had ≥1.5 D. Anti-VEGF treated eyes showed less myopia (p<0.009), with no BCVA or astigmatism difference (p=0.997, p=0.271) compared to laser-treated eyes. Conclusion: One-quarter of the eyes exhibited good visual acuity (Snellen BCVA of 20/20 or better) 5 years post-ROP treatment. Refractive errors were common. Anti-VEGF therapy may be superior to laser therapy in terms of myopic refractive error.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Ophthalmology,General Medicine